Eligard 7.5 mg (Leuprolide Acetate POWDER FOR SUSPENSION, SUSTAINED-RELEASE) 7.5 MG

Eligard 7.5 mg is a sustained-release leuprolide acetate powder for subcutaneous injection. It is commonly used for hormone-related conditions, including prostate cancer. This long-acting formulation is designed for convenient administration.

Strength

7.5 MG

Pack Size

0.25ML

Manufacturer / TM Owner

TOLMAR INTERNATIONAL LTD.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Eligard 7.5 mg is primarily used for the management of advanced prostate cancer. Leuprolide acetate, the active ingredient, works by reducing the production of certain hormones. This medication is often prescribed as part of a broader treatment plan for hormone-sensitive conditions.

Side Effects

Common effects of Eligard 7.5 mg may include temporary discomfort at the injection site, hot flashes, and fatigue. Some users may experience changes in mood or energy levels. These effects vary and are not exhaustive; individual experiences may differ.

Precautions & Warnings

Eligard 7.5 mg should be handled with care, as it is a sustained-release formulation. It is important to follow the prescribed administration guidelines and store the medication properly. Always consult a healthcare provider before starting or stopping any medication.

Avoid Interactions

Leuprolide acetate may interact with other medications, including those that affect hormone levels. It is important to inform your healthcare provider about all medications you are taking. Alcohol and certain supplements may also interact with this medication.

Frequently Asked Questions

Eligard 7.5 mg is primarily used for the management of advanced prostate cancer. It works by reducing the production of certain hormones.

Eligard 7.5 mg is administered as a subcutaneous injection. It is a sustained-release formulation designed for convenient administration.

Common effects may include temporary discomfort at the injection site, hot flashes, and fatigue. Individual experiences may vary.

Leuprolide acetate may interact with other medications. It is important to inform your healthcare provider about all medications you are taking.

Eligard 7.5 mg should be stored according to the manufacturer's guidelines. Always follow the prescribed administration and storage instructions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.